Fidaxomicin Use in the Pediatric Population with Clostridioides difficile

References

• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–834. doi:10.1056/NEJMoa1408913
   PubMed Web of Science ®Google Scholar
• Wendt JM, Cohen JA, Mu Y, et al. Clostridium difficile infection among children across diverse US geographic locations. Pediatrics. 2014;133(4):651–658. doi:10.1542/peds.2013-3049
   PubMed Web of Science ®Google Scholar
• Miranda-Katz M, Parmar D, Dang R, Alabaster A, Greenhow TL. Epidemiology and risk factors for community associated clostridioides difficile in children. J Pediatr. 2020;221:99–106. doi:10.1016/j.jpeds.2020.02.005
   PubMed Web of Science ®Google Scholar
• Adams DJ, Barone JB, Nylund CM. Community-associated clostridioides difficile infection in children: a review of recent literature. J Pediatric Infect Dis Soc. 2021;2021(10):S22–S26. doi:10.1093/jpids/piab064
   Web of Science ®Google Scholar
• Crews JD, Anderson LR, Waller DK, Swartz MD, DuPont HL, Starke JR. Risk factors for community-associated clostridium difficile-associated diarrhea in children. Pediatr Infect Dis J. 2015;34(9):919–923. doi:10.1097/INF.0000000000000767
   PubMed Web of Science ®Google Scholar
• Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol. 2008;190(7):2505–2512. doi:10.1128/JB.01765-07
   PubMed Web of Science ®Google Scholar
• Chilton CH, Pickering DS, Freeman J. Microbiologic factors affecting clostridium difficile recurrence. Clin Microbiol Infect. 2018;24(5):476–482. doi:10.1016/j.cmi.2017.11.017
   PubMed Web of Science ®Google Scholar
• Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55(Suppl 2):S132–42. doi:10.1093/cid/cis338
   PubMed Web of Science ®Google Scholar
• Vaughn BP, Kaiser T, Staley C, et al. A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis. Clin Exp Gastroenterol. 2019;12:9–19. doi:10.2147/CEG.S186097
   PubMed Web of Science ®Google Scholar
• Vrieze A, Out C, Fuentes S, et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol. 2014;60(4):824–831. doi:10.1016/j.jhep.2013.11.034
   PubMed Web of Science ®Google Scholar
• Administration USFD. Search orphan drug designation and approval; 2022. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=325210. Accessed September 15, 2022.
   Google Scholar
• Merck. FDA approves merck’s DIFICID (fidaxomicin) to treat clostridioides difficile in children aged six months and older; 2020. Available from: https://www.merck.com/news/fda-approves-mercks-dificid-fidaxomicin-to-treat-clostridioides-difficile-in-children-aged-six-months-and-older/. Accessed August 30, 2022.
   Google Scholar
• Giancola SE, Williams RJ 2nd, Gentry CA. Evaluation of fidaxomicin usage patterns and outcomes for clostridium difficile infection across the United States veterans health administration. J Clin Pharm Ther. 2018;43(3):353–358. doi:10.1111/jcpt.12663
   PubMed Web of Science ®Google Scholar
• Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029–e1044. doi:10.1093/cid/ciab549
   PubMed Web of Science ®Google Scholar
• O’Gorman MA, Michaels MG, Kaplan SL, et al. Safety and pharmacokinetic study of fidaxomicin in children with clostridium difficile-associated diarrhea: a phase 2a multicenter clinical trial. J Pediatr Infect Dis Soc. 2018;7(3):210–218. doi:10.1093/jpids/pix037
   PubMed Web of Science ®Google Scholar
• Wolf J, Kalocsai K, Fortuny C, et al. Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with clostridioides (clostridium) difficile infection: a phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE). Clin Infect Dis. 2020;71(10):2581–2588. doi:10.1093/cid/ciz1149
   PubMed Web of Science ®Google Scholar
• Freeman J, Vernon J, Pilling S, et al. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011–2014. Clin Microbiol Infect. 2018;24(7):724–731. doi:10.1016/j.cmi.2017.10.008
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422–431. doi:10.1056/NEJMoa0910812
   PubMed Web of Science ®Google Scholar
• DIFICID® (Fidaxomicin) [package insert]. Whitehouse station, NJ: Merck & Co., Inc, 2020.
   Google Scholar
• Smeltzer S, Hassoun A. Successful use of fidaxomicin in recurrent Clostridium difficile infection in a child. J Antimicrob Chemother. 2013;68(7):1688–1689. doi:10.1093/jac/dkt079
   PubMed Web of Science ®Google Scholar
• Sammons JS, Gerber JS, Tamma PD, et al. Diagnosis and management of clostridium difficile infection by pediatric infectious diseases physicians. J Pediatr Infect Dis Soc. 2014;3(1):43–48. doi:10.1093/jpids/pit065
   PubMedGoogle Scholar
• Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281–289. doi:10.1016/S1473-3099(11)70374-7
   PubMed Web of Science ®Google Scholar
• Diorio C, Robinson PD, Ammann RA, et al. Guideline for the management of clostridium difficile infection in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2018;36(31):3162–3171. doi:10.1200/JCO.18.00407
   PubMed Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48. doi:10.1093/cid/cix1085
   PubMed Web of Science ®Google Scholar
• Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124–1147. doi:10.14309/ajg.0000000000001278
   PubMed Web of Science ®Google Scholar
• Buchler AC, Rampini SK, Stelling S, et al. Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich. BMC Infect Dis. 2014;14:607. doi:10.1186/s12879-014-0607-z
   PubMed Web of Science ®Google Scholar
• Sholeh M, Krutova M, Forouzesh M, et al. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020;9(1):158. doi:10.1186/s13756-020-00815-5
   PubMed Web of Science ®Google Scholar
• Liubakka A, Vaughn BP. Clostridium difficile infection and fecal microbiota transplant. AACN Adv Crit Care. 2016;27(3):324–337. doi:10.4037/aacnacc2016703
   PubMed Web of Science ®Google Scholar
• Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent clostridium difficile-associated diarrhea. J Infect Dis. 2008;197(3):435–438. doi:10.1086/525047
   PubMed Web of Science ®Google Scholar
• Krutova M, de Meij TGJ, Fitzpatrick F, Drew RJ, Wilcox MH, Kuijper EJ. How to: clostridioides difficile infection in children. Clin Microbiol Infect. 2022;28(8):1085–1090. doi:10.1016/j.cmi.2022.03.001
   PubMed Web of Science ®Google Scholar
• Nguyen LH, Ortqvist AK, Cao Y, et al. Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. Lancet Gastroenterol Hepatol. 2020;5(11):986–995. doi:10.1016/S2468-1253(20)30267-3
   PubMed Web of Science ®Google Scholar
• Marild K, Ye W, Lebwohl B, et al. Antibiotic exposure and the development of coeliac disease: a nationwide case-control study. BMC Gastroenterol. 2013;13:109. doi:10.1186/1471-230X-13-109
   PubMed Web of Science ®Google Scholar
• Lavebratt C, Yang LL, Giacobini M, et al. Early exposure to antibiotic drugs and risk for psychiatric disorders: a population-based study. Transl Psychiatry. 2019;9(1):317. doi:10.1038/s41398-019-0653-9
   PubMed Web of Science ®Google Scholar
• Du C, Luo Y, Walsh S, Grinspan A. Oral fecal microbiota transplant capsules are safe and effective for recurrent clostridioides difficile infection: a systematic review and meta-analysis. J Clin Gastroenterol. 2021;55(4):300–308. doi:10.1097/MCG.0000000000001495
   PubMed Web of Science ®Google Scholar
• Nicholson MR, Mitchell PD, Alexander E, et al. Efficacy of fecal microbiota transplantation for clostridium difficile infection in children. Clin Gastroenterol Hepatol. 2020;18(3):612–619 e1. doi:10.1016/j.cgh.2019.04.037
   PubMed Web of Science ®Google Scholar
• Ronan V, Yeasin R, Claud EC. Childhood development and the microbiome-the intestinal microbiota in maintenance of health and development of disease during childhood development. Gastroenterology. 2021;160(2):495–506. doi:10.1053/j.gastro.2020.08.065
   PubMed Web of Science ®Google Scholar
• Rajasingham R, Enns EA, Khoruts A, Vaughn BP. Cost-effectiveness of treatment regimens for clostridioides difficile infection: an evaluation of the 2018 Infectious Diseases Society of America guidelines. Clin Infect Dis. 2020;70(5):754–762. doi:10.1093/cid/ciz318
   PubMed Web of Science ®Google Scholar
• Aby ES, Vaughn BP, Enns EA, Rajasingham R. Cost-effectiveness of fecal microbiota transplantation for first recurrent Clostridioides difficile infection. Clin Infect Dis. 2022. doi:10.1093/cid/ciac207
   PubMed Web of Science ®Google Scholar
• Markovic V, Kostic M, Ilickovic I, Jankovic SM. Cost-effectiveness comparison of fidaxomicin and vancomycin for treatment of clostridium difficile infection: a Markov model based on data from a South West Balkan country in socioeconomic transition. Value Health Reg Issues. 2014;4:87–94. doi:10.1016/j.vhri.2014.08.001
   PubMedGoogle Scholar
• Watt M, McCrea C, Johal S, Posnett J, Nazir J. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany. Infection. 2016;44(5):599–606. doi:10.1007/s15010-016-0894-y
   PubMed Web of Science ®Google Scholar
• Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health. 2013;16(2):297–304. doi:10.1016/j.jval.2012.11.004
   PubMed Web of Science ®Google Scholar
• Schutze GE, Willoughby RE. Clostridium difficile infection in infants and children. Pediatrics. 2013;131(1):196–200. doi:10.1542/peds.2012-2992
   PubMed Web of Science ®Google Scholar
• van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27:S1–S21. doi:10.1016/j.cmi.2021.09.038
   PubMed Web of Science ®Google Scholar
• Wu KS, Syue LS, Cheng A, et al. Recommendations and guidelines for the treatment of Clostridioides difficile infection in Taiwan. J Microbiol Immunol Infect. 2020;53(2):191–208. doi:10.1016/j.jmii.2020.02.002
   PubMedGoogle Scholar
• Nana T, Moore C, Boyles T, et al. South African Society of Clinical Microbiology clostridioides difficile infection diagnosis, management and infection prevention and control guideline. Southern Afr J Infect Dis. 2020;35(1):1–26. doi:10.4102/sajid.v35i1.219
   Web of Science ®Google Scholar
• Langer S. Resolution of the Federal Joint Committee: fidaxomicin for children and adolescents with Clostridioides difficile infection. Arzneimitteltherapie. 2020;38(11):482.
   Google Scholar